[Chronic bronchitis: when are antibiotics indicated?].

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Microbiology

Context:

• Chronic obstructive pulmonary disease (COPD) exacerbations are often linked to bacterial infections.
• The precise role of bacterial pathogens and the efficacy of antimicrobial chemotherapy in COPD management remain incompletely understood.
• Current clinical guidelines offer limited direction on optimal antibiotic strategies for COPD patients.

Purpose:

• To elucidate the significance of bacterial infections in the pathogenesis of COPD.
• To define the appropriate role and duration of antimicrobial chemotherapy during COPD exacerbations.
• To identify the most suitable oral antibiotic agents for treating bacterial infections in COPD patients.

Summary:

• Bacterial infections play a complex role in COPD, with their impact on exacerbations still under investigation.
• Antibiotic therapy, lasting seven to ten days, is advised specifically for Anthonisen type-1 exacerbations, characterized by increased sputum production and purulence.
• For other COPD exacerbations, routine antibiotic use is not supported by current evidence.
• The selection of antibiotics should prioritize agents with good tolerability, low toxicity, and cost-effectiveness, while demonstrating efficacy against common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae.
• Aminopenicillins and cotrimoxazole are suggested as appropriate choices meeting these criteria.

Impact:

• Provides evidence-based recommendations for targeted antibiotic use in COPD exacerbations.
• Aims to optimize patient outcomes by preventing unnecessary antibiotic exposure and reducing the risk of antimicrobial resistance.
• Guides clinicians in selecting appropriate, safe, and cost-effective antimicrobial agents for specific COPD patient populations.